Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Enhancing Regulatory Science for Advancing Pharmaceutical Quality and Manufacturing (U01) Clinical Trials Optional
BackgroundFDA regulates pharmaceutical drug products to ensure a continuous supply of high quality drugs in the United States.
In regulating the pharmaceutical manufacturing sector, new technologies can improve drug quality, address shortages of medicines, and lower drug costs.
To help
achieve this, FDA encourages development and adoption of emerging manufacturing technology to modernize pharmaceutical manufacturing.
Advanced manufacturing holds great promise for improving the American market for drugs and biologicals and, results in a more robust manufacturing process with fewer interruptions in production, fewer product failures (before or after distribution), and greater assurance that the drug products manufactured in any given period of time will provide the expected clinical performance.
In other words, encouraging the development and adoption of emerging manufacturing technologies may lead to improved manufacturing, and therefore improved product quality and availability throughout a product’s lifecycle.The complexity of drug products has been increasing over the years, in part due to, the increasing number of poorly soluble drugs, targeted drug delivery to traditionally un-druggable sites, and increasing focus on personalized and precision medicine.
In the realm of drug products, complexity may arise from the active ingredient, the formulation, the dosage form, etc.
In order to prepare for the increase in complex products, the Office of Pharmaceutical Quality is considering best practices and paths forward in the risk-based quality assessment of complex drug products.
While the development of emerging technology is critical to modernizing pharmaceutical manufacturing and improving quality, FDA also recognizes that the implementation of emerging technology could present challenges to both industry and FDA.
By the very nature of an approach being new or innovative in pharmaceutical industry, a limited knowledge and experiential base about the technology may exist.
This program aims to address knowledge and experience gaps identified for emerging manufacturing technology and support the development and adoption of such technology in the pharmaceutical sector.Project ObjectivesThe goal of this program is to support the advancement of regulatory science that can (1) facilitate the implementation and the assessment of emerging manufacturing technology in the pharmaceutical sector; (2) expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug productsIdentified emerging technologies should be sufficiently developed and likely ready for industrial implementation for the purpose of product quality enhancement.
The results and knowledge developed in this program can be utilized by industry, academia, and industry to support the implementation of the identified emerging technologies and to ensure that FDA regulatory policies reflect state-of-the-art manufacturing science.
Specifically, the expected project outcomes should enable (1) developing tools and approaches for risk-based quality assessment, (2) establishing science-based quality standards and policies, and/or (3) providing training tools for both the industry and/or the regulatory bodies for the identified emerging technology.Potential research projects could include those that focus on characterizing complex drug substances (including botanical drug substances) and complex drug product dosage forms.
Projects could include related control strategies to ensure the product quality, especially those which can help solve potential regulatory questions related to drug quality.
Specific topics could relate to the following:
1. Appropriate analytical methods for complex drug substances or products 2. In-process controls during manufacturing processes to ensure product quality 3. Raw material quality controlNOTE:
Proposals should clearly describe the potential impacts of the proposed technology on readiness for broad implementation in pharmaceutical industry, control strategy, and/or regulatory evaluation for complex drug substances and complex drug product dosage forms.
In regulating the pharmaceutical manufacturing sector, new technologies can improve drug quality, address shortages of medicines, and lower drug costs.
To help
achieve this, FDA encourages development and adoption of emerging manufacturing technology to modernize pharmaceutical manufacturing.
Advanced manufacturing holds great promise for improving the American market for drugs and biologicals and, results in a more robust manufacturing process with fewer interruptions in production, fewer product failures (before or after distribution), and greater assurance that the drug products manufactured in any given period of time will provide the expected clinical performance.
In other words, encouraging the development and adoption of emerging manufacturing technologies may lead to improved manufacturing, and therefore improved product quality and availability throughout a product’s lifecycle.The complexity of drug products has been increasing over the years, in part due to, the increasing number of poorly soluble drugs, targeted drug delivery to traditionally un-druggable sites, and increasing focus on personalized and precision medicine.
In the realm of drug products, complexity may arise from the active ingredient, the formulation, the dosage form, etc.
In order to prepare for the increase in complex products, the Office of Pharmaceutical Quality is considering best practices and paths forward in the risk-based quality assessment of complex drug products.
While the development of emerging technology is critical to modernizing pharmaceutical manufacturing and improving quality, FDA also recognizes that the implementation of emerging technology could present challenges to both industry and FDA.
By the very nature of an approach being new or innovative in pharmaceutical industry, a limited knowledge and experiential base about the technology may exist.
This program aims to address knowledge and experience gaps identified for emerging manufacturing technology and support the development and adoption of such technology in the pharmaceutical sector.Project ObjectivesThe goal of this program is to support the advancement of regulatory science that can (1) facilitate the implementation and the assessment of emerging manufacturing technology in the pharmaceutical sector; (2) expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug productsIdentified emerging technologies should be sufficiently developed and likely ready for industrial implementation for the purpose of product quality enhancement.
The results and knowledge developed in this program can be utilized by industry, academia, and industry to support the implementation of the identified emerging technologies and to ensure that FDA regulatory policies reflect state-of-the-art manufacturing science.
Specifically, the expected project outcomes should enable (1) developing tools and approaches for risk-based quality assessment, (2) establishing science-based quality standards and policies, and/or (3) providing training tools for both the industry and/or the regulatory bodies for the identified emerging technology.Potential research projects could include those that focus on characterizing complex drug substances (including botanical drug substances) and complex drug product dosage forms.
Projects could include related control strategies to ensure the product quality, especially those which can help solve potential regulatory questions related to drug quality.
Specific topics could relate to the following:
1. Appropriate analytical methods for complex drug substances or products 2. In-process controls during manufacturing processes to ensure product quality 3. Raw material quality controlNOTE:
Proposals should clearly describe the potential impacts of the proposed technology on readiness for broad implementation in pharmaceutical industry, control strategy, and/or regulatory evaluation for complex drug substances and complex drug product dosage forms.
Agency: Department of Health and Human Services
Office: Food and Drug Administration
Estimated Funding: $10,000,000
Office: Food and Drug Administration
Estimated Funding: $10,000,000
Who's Eligible
Obtain Full Opportunity Text:
Full Announcement
Additional Information of Eligibility:
Eligible OrganizationsHigher Education InstitutionsPublic/State Controlled Institutions of Higher EducationPrivate Institutions of Higher EducationThe following types of Higher Education Institutions are always encouraged to apply for FDA support as Public or Private Institutions of Higher Education:o Hispanic-serving Institutionso Historically Black Colleges and Universities (HBCUs)o Tribally Controlled Colleges and Universities (TCCUs)o Alaska Native and Native Hawaiian Serving Institutionso Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)Nonprofits Other Than Institutions of Higher EducationNonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)For-Profit OrganizationsSmall BusinessesFor-Profit Organizations (Other than Small Businesses)GovernmentsState GovernmentsCounty GovernmentsCity or Township GovernmentsSpecial District GovernmentsIndian/Native American Tribal Governments (Federally Recognized)Indian/Native American Tribal Governments (Other than Federally Recognized)U. S. Territory or PossessionOtherIndependent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions)
Full Opportunity Web Address:
https://grants.nih.gov/grants/guide/pa-files/PAR-20-083.html
Contact:
Agency Email Description:
Work Email
Agency Email:
Date Posted:
2020-01-08
Application Due Date:
Archive Date:
2022-05-02
Social Entrepreneurship
Spotlight
Why People Buy from Social Enterprises?
The Guardian has compiled a list of responses to its latest open thread, and has announced the winner of the social enterprise gift hamper packed with presents.
Learn How to Identify and Avoid Grant Scams
